Sign In
Buy FEMY
$2.86
-0.0500 (-1.72%)
At Close: Jul 31, 2026
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
11:45am, Tuesday, 10'th Sep 2024
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
08:30am, Monday, 09'th Sep 2024
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currentl
Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting
08:30am, Thursday, 05'th Sep 2024
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
10:46am, Tuesday, 03'rd Sep 2024
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
08:30am, Tuesday, 03'rd Sep 2024
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
08:30am, Thursday, 29'th Aug 2024
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offi
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
08:30am, Tuesday, 27'th Aug 2024
The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
10:45am, Thursday, 08'th Aug 2024
Femasys Inc. (FEMY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
08:30am, Thursday, 08'th Aug 2024
Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio Company gained CE Mark approval for four of its women's
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
08:30am, Thursday, 27'th Jun 2024
Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products Leading women's reproductive health conference directly follows the company's
Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Ce
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council
08:30am, Thursday, 16'th May 2024
Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
10:40am, Thursday, 09'th May 2024
Femasys Inc. (FEMY) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
08:30am, Thursday, 09'th May 2024
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) --
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
08:30am, Tuesday, 07'th May 2024
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
